Week Ending July 5, 2022

Lung Cancer Treatment Efficacy Not Directly Affected by COVID-19, Study Finds
“A new analysis of patients treated for lung cancer in a French health system suggests the COVID-19 pandemic led to an initial drop in new cases but that the efficacy of most treatment modalities was not significantly affected.”

KRYSTAL-12 Investigators Seek to Confirm Adagrasib’s Role in KRAS G12C–Mutant NSCLC
“Efforts to unlock treatment modalities targeting KRAS mutations have ebbed and flowed for patients with non–small cell lung (NSCLC) as investigators face resistance, intolerable toxicity profiles, and a lack of available binding pockets to guide treatment development.1

Philips incorporates Biodesix blood-based proteomic nodule risk assessment testing into Lung Cancer Orchestrator to advance early lung cancer diagnosis
“Solution adds proteomic analysis of blood-based biomarkers to Philips Lung Cancer Orchestrator to better assess the risk of lung nodule malignancy, enhancing decision-making for diagnosis and treatment”

$5.3 million grant supports research into lung cancer recurrence
“Researchers at Washington University School of Medicine in St. Louis are leading a national study aimed at identifying patients with early-stage lung cancer who are at high risk of having the cancer return, even after surgery and chemotherapy appear to have eliminated their tumors.”

Penn Medicine awarded $9 million to advance study of technology that lights up lung cancer tumors
“A grant from the National Cancer Institute will build on Penn’s pioneering role in the use of intraoperative imaging technology that makes it easier and safer to remove tumors on or in the lungs”

Durvalumab Plus Chemotherapy Yield Statistically Significant Responses in Resectable NSCLC
“Results from the phase 3 AEGEAN trial showed an improved pathological complete response in patients with resectable non–small cell lung cancer treated with durvalumab plus neoadjuvant chemotherapy vs chemotherapy alone.”

Roundtable Discussion: Sabari Evaluates Immunotherapy, Targeted Therapy Options in ES-SCLC
“During a case-based roundtable event, Joshua K. Sabari, MD, an assistant professor in the Department of Medicine at NYU Grossman School of Medicine and medical director at NYU Langone Health/Perlmutter Cancer Center in New York, NY, discussed the case of a 73-year-old woman with extensive-stage small cell lung cancer (ES-SCLC).”

Insight into Cancer Vaccines
“With the recent upsurge in virology and vaccine production due to the COVID-19 pandemic, medical professionals rely more on this new modus operandi. One prominent example is the use of “cancer vaccines,” a relatively new technology in the field of oncology, first adopted just two decades prior.”

Cleveland Clinic Researchers Shed New Light on Importance of Cellular Interactions in Targeted Therapy Resistance in Lung Cancer
“New Cleveland Clinic research has uncovered key information about cellular interaction between tumor cells and normal tissue, providing better understanding of how therapeutic resistance develops”